• 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016
• A phase 1 study of the Janus kinase 2 (JAK2)^V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
• Abstracts from the 3rd International Genomic Medicine Conference (3rd IGMC 2015) : Jeddah, Kingdom of Saudi Arabia. 30 November - 3 December 2015
• Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding
• Characterization of a novel autosomal dominant bleeding disorder in a large kindred from east Texas
• Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIalpha
• Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα
• CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse
• Current Overview on Hypercoagulability in COVID-19
• Depression and anxiety in persons with Von Willebrand disease
• Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Essential Thrombocythemia Enrolled in the MOST Study
• Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis
• F5-Atlanta: A novel mutation in F5 associated with enhanced East Texas splicing and FV-short production
• Factor V east Texas variant causes bleeding in a three-generation family
• Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder
• Genome-Wide Association Transethnic Meta-Analyses Identifies Novel Associations Regulating Coagulation Factor VIII and von Willebrand Factor Plasma Levels
• Guidelines for the performance of minimally invasive splenectomy
• Human genome meeting 2016 : Houston, TX, USA. 28 February - 2 March 2016
• Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States
• Inherited disorders of the fibrinolytic pathway
• Natural anticoagulant discovery, the gift that keeps on giving: finding FV-Short
• New clotting disorders that cast new light on blood coagulation and may play a role in clinical practice
• New data on FII, FV, FIX and thrombomodulin defects: blood keeps clotting in normal and in peculiar ways
• New insights into the biology of tissue factor pathway inhibitor
• Sepsis-Related Outcomes of Patients with Philadelphia-Negative Myeloproliferative Neoplasms
• The spectrum and severity of bleeding in adolescents with low von Willebrand factor-associated heavy menstrual bleeding
• Thromboelastography and rotational thromboelastometry in bleeding patients with coagulopathy: Practice management guideline from the Eastern Association for the Surgery of Trauma
• Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein
• Validation Study of the Composite Score to Identify Von Willebrand Disease in Children